These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29768767)

  • 41. Theranostics in primary care: pharmacogenomics tests and beyond.
    Bartlett G; Antoun J; Zgheib NK
    Expert Rev Mol Diagn; 2012 Nov; 12(8):841-55. PubMed ID: 23249202
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Membrane transporters and drug development: relevance to pharmacogenomics, nutrigenomics, epigenetics, and systems biology.
    Yan Q
    Methods Mol Biol; 2010; 637():1-21. PubMed ID: 20419427
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolomics and Personalized Medicine.
    Koen N; Du Preez I; Loots du T
    Adv Protein Chem Struct Biol; 2016; 102():53-78. PubMed ID: 26827602
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Future perspectives of personalized medicine in traditional Chinese medicine: a systems biology approach.
    Zhang A; Sun H; Wang P; Han Y; Wang X
    Complement Ther Med; 2012; 20(1-2):93-9. PubMed ID: 22305254
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glaucomics: a call for systems diagnostics for 21(st) century ophthalmology and personalized visual health.
    Güngör K; Hotez PJ; Özdemir V; Aynacıoğlu Ş
    OMICS; 2014 May; 18(5):275-9. PubMed ID: 24730382
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolomics: integration of a new "omics" with clinical pharmacology.
    James LP
    Clin Pharmacol Ther; 2013 Nov; 94(5):547-51. PubMed ID: 24145711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Melding regulatory, pharmaceutical industry, and U.S. payer perspectives on improving approaches to heterogeneity of treatment effect in research and practice.
    Willke RJ; Crown W; Del Aguila M; Cziraky MJ; Khan ZM; Migliori R
    Value Health; 2013; 16(6 Suppl):S10-5. PubMed ID: 24034306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Academia at the crossroads: education and training in pharmacogenomics.
    Lesko LJ; Johnson JA
    Per Med; 2012 Jul; 9(5):497-506. PubMed ID: 29768769
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom's law.
    Schulthess D; Chlebus M; Bergstrӧm R; Baelen KV
    Chin Clin Oncol; 2014 Jun; 3(2):21. PubMed ID: 25841417
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
    Loo TT; Ross CJ; Sistonen J; Visscher H; Madadi P; Koren G; Hayden MR; Carleton BC
    Pharmacogenomics; 2010 Sep; 11(9):1269-85. PubMed ID: 20860467
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacometabonomics and personalized medicine.
    Everett JR; Loo RL; Pullen FS
    Ann Clin Biochem; 2013 Nov; 50(Pt 6):523-45. PubMed ID: 23888060
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Working towards personalization in medicine: main obstacles to reaching this vision from today's perspective.
    Leyens L; Horgan D; Lal JA; Steinhausen K; Satyamoorthy K; Brand A
    Per Med; 2014 Sep; 11(7):641-649. PubMed ID: 29764055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States.
    Frueh FW
    Value Health; 2013; 16(6 Suppl):S27-31. PubMed ID: 24034309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review.
    Dietel M; Sers C
    Virchows Arch; 2006 Jun; 448(6):744-55. PubMed ID: 16736190
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BeadArray-based solutions for enabling the promise of pharmacogenomics.
    Fan JB; Hu SX; Craumer WC; Barker DL
    Biotechniques; 2005 Oct; 39(4):583-8. PubMed ID: 16235573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Crossing the Boundaries of Our Current Healthcare System by Integrating Ultra-Weak Photon Emissions with Metabolomics.
    Burgos RC; van Wijk EP; van Wijk R; He M; van der Greef J
    Front Physiol; 2016; 7():611. PubMed ID: 28018239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ethical, Economic, Societal, Clinical, and Pharmacology Uncertainties Associated With Milasen and Other Personalized Drugs.
    Amariles P; Madrigal-Cadavid J
    Ann Pharmacother; 2020 Sep; 54(9):937-938. PubMed ID: 32126811
    [No Abstract]   [Full Text] [Related]  

  • 59. Resistance Training Data Analysis on Blood and Personal Profiles for Customized Healthcare.
    So WY; Jeong TT
    Iran J Public Health; 2018 Jul; 47(7):1037-1038. PubMed ID: 30182004
    [No Abstract]   [Full Text] [Related]  

  • 60. Development of a triculture based system for improved benefit/risk assessment in pharmacology and human food.
    Bazes A; Nollevaux G; Coco R; Joly A; Sergent T; Schneider YJ
    BMC Proc; 2011; 5 Suppl 8(Suppl 8):P67. PubMed ID: 22373431
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.